Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia

Journal of Lipid Research

Volumn 50, Issue 7, 2009, Pages 1463-1471

  Tremblay, André J ^a,b   Lamarche, Benoît ^a,b   Hogue, Jean Charles ^a,b   Couture, Patrick ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Apolipoprotein B 100; Apolipoprotein B 48; Cholesterol absorption and synthesis; Gas chromatography mass spectrometry; Intestine; Kinetic; Liver

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CAMPESTEROL; EZETIMIBE; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; SITOSTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL ABSORPTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; INHIBITION KINETICS; INTESTINE SECRETION; LIPID ABSORPTION; LIPOPROTEIN BLOOD LEVEL; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; PLACEBOS; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 67650552637     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P800061-JLR200     Document Type: Article

References (61)

1. Executive Summary of The Third Report of TheNational Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001. JAMA. 285: 2486-2497.
2. Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360: 7-22.
3. LaRosa, J. C., J. He, and S. Vupputuri. 1999. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 282: 2340-2346.
4. Law, M. R., N. J.Wald, and A. R. Rudnicka. 2003. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 326: 1423.
5. Tilvis, R. S., and T. A. Miettinen. 1986. Serum plant sterols and their relation to cholesterol absorption. Am. J. Clin. Nutr. 43: 92-97.
6. Matthan, N. R., M. Raeini-Sarjaz, A. H. Lichtenstein, L. M. Ausman, and P. J. Jones. 2000. Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women. Lipids. 35: 1037-1044.
7. Rajaratnam, R. A., H. Gylling, and T. A. Miettinen. 2000. Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women. J. Am. Coll. Cardiol. 35: 1185-1191.
8. Cuchel, M., E. J. Schaefer, J. S. Millar, P. J. Jones, G. G. Dolnikowski, C. Vergani, and A. H. Lichtenstein. 1997. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males. Arterioscler. Thromb. Vasc. Biol. 17: 1910-1917.
9. Cortner, J. A., M. J. Bennett, N. A. Le, and P. M. Coates. 1993. The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia. J. Inherit. Metab. Dis. 16: 127-134.
10. Bilheimer, D. W., S. M. Grundy, M. S. Brown, and J. L. Goldstein. 1983. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. USA. 80: 4124-4128.
11. Malmendier, C. L., J. F. Lontie, C. Delcroix, and T. Magot. 1989. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis. 80: 101-109.
12. Parhofer, K. G., P. H. Barrett, J. Dunn, and G. Schonfeld. 1993. Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. Clin. Investig. 71: 939-946.
13. Watts, G. F., P. H. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson. 2003. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 52: 803-811.
14. Van Heek, M., C. F. France, D. S. Compton, R. L. McLeod, N. P. Yumibe, K. B. Alton, E. J. Sybertz, and H. R. Davis, Jr. 1997. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther. 283: 157-163.
15. van Heek, M., C. Farley, D. S. Compton, L. Hoos, K. B. Alton, E. J. Sybertz, and H. R. Davis, Jr. 2000. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. 129: 1748-1754.
16. Garcia-Calvo, M., J. Lisnock, H. G. Bull, B. E. Hawes, D. A. Burnett, M. P. Braun, J. H. Crona, H. R. Davis, Jr., D. C. Dean, P. A. Detmers, et al. 2005. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA. 102: 8132-8137.
17. Altmann, S. W., H. R. Davis, Jr., L. J. Zhu, X. Yao, L. M. Hoos, G. Tetzloff, S. P. Iyer, M. Maguire, A. Golovko, M. Zeng, et al. 2004. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 303: 1201-1204.
18. Sane, A. T., D. Sinnett, E. Delvin, M. Bendayan, V. Marcil, D. Menard, J. F. Beaulieu, and E. Levy. 2006. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J. Lipid Res. 47: 2112-2120.
19. Ballantyne, C. M., J. Houri, A. Notarbartolo, L. Melani, L. J. Lipka, R. Suresh, S. Sun, A. P. LeBeaut, P. T. Sager, and E. P. Veltri. 2003. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 107: 2409-2415.
20. Davidson, M. H., T. McGarry, R. Bettis, L. Melani, L. J. Lipka, A. P. LeBeaut, R. Suresh, S. Sun, and E. P. Veltri. 2002. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40: 2125-2134.
21. Melani, L., R. Mills, D. Hassman, R. Lipetz, L. Lipka, A. LeBeaut, R. Suresh, P. Mukhopadhyay, and E. Veltri. 2003. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur. Heart J. 24: 717-728.
22. Kerzner, B., J. Corbelli, S. Sharp, L. J. Lipka, L. Melani, A. LeBeaut, R. Suresh, P. Mukhopadhyay, and E. P. Veltri. 2003. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol. 91: 418-424.
23. Telford, D. E., B. G. Sutherland, J. Y. Edwards, J. D. Andrews, P. H. Barrett, and M. W. Huff. 2007. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J. Lipid Res. 48: 699-708.
24. MacLean, D. R., A. Petrasovits, P.W. Connelly, M. Joffres, B.O'Connor, and J. A. Little. 1999. Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults. Canadian Heart Health Surveys Research Group. Can. J. Cardiol. 15: 434-444.
25. Harris, J., and F. Benedict. 1919. A Biometric Study of Basal Metabolism in Man. Carnegie Institution, Washington, DC.
26. Moorjani, S., A. Dupont, F. Labrie, P. J. Lupien, D. Brun, C. Gagné, M. Giguère, and A. Bélanger. 1987. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 36: 244-250.
27. Havel, R. J., H. Eder, and J. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
28. Albers, J. J., G. R. Warnick, D. Wiebe, P. King, P. Steiner, L. Smith, C. Breckenridge, A. Chow, K. Kuba, S. Weidman, et al. 1978. Multilaboratory comparison of three heparin-Mn21 precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin. Chem. 24: 853-856.
29. Matthan, N. R., A. Giovanni, E. J. Schaefer, B. G. Brown, and A. H. Lichtenstein. 2003. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J. Lipid Res. 44: 800-806.
30. Kotite, L., N. Bergeron, and R. J. Havel. 1995. Quantification of apolipoproteins B-100, B-48, and E in human triglyceride-rich lipoproteins. J. Lipid Res. 36: 890-900.
31. Zilversmit, D. B., and T. M. Shea. 1989. Quantitation of apoB-48 and apoB-100 by gel scanning or radio-iodination. J. Lipid Res. 30: 1639-1646.
32. Welty, F. K., A. H. Lichtenstein, P. H. Barrett, G. G. Dolnikowski, and E. J. Schaefer. 1999. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler. Thromb. Vasc. Biol. 19: 2966-2974.
33. Dwyer, K. P., P. H. Barrett, D. Chan, J. I. Foo, G. F. Watts, and K. D. Croft. 2002. Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. J. Lipid Res. 43: 344-349.
34. Cobelli, C., G. Toffolo, D. M. Bier, and R. Nosadini. 1987. Models to interpret kinetic data in stable isotope tracer studies. Am. J. Physiol. 253: E551-E564.
35. Tremblay, A. J., B. Lamarche, I. Ruel, J. C. Hogue, J. Bergeron, C. Gagné, and P. Couture. 2004. Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation. Atherosclerosis. 172: 367-373.
36. Welty, F. K., A. H. Lichtenstein, P. H. Barrett, G. G. Dolnikowski, J. M. Ordovas, and E. J. Schaefer. 1997. Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. Arterioscler. Thromb. Vasc. Biol. 17: 881-888.
37. Phair, R. D., M. G. Hammond, J. A. Bowden, M. Fried, W. R. Fisher, and M. Berman. 1975. Preliminary model for human lipoprotein metabolism in hyperlipoproteinemia. Fed. Proc. 34: 2263-2270.
38. Cohn, J., D. Wagner, S. Cohn, J. Millar, and E. Schaefer. 1990. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J. Clin. Invest. 85: 804-811.
39. Ballantyne,C.M.,M.A.Blazing,T.R.King,W.E. Brady, andJ. Palmisano. 2004. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93: 1487-1494.
40. Feldman, T., M. Koren, W. Insull, Jr., J. McKenney, H. Schrott, A. Lewin, S. Shah, M. Sidisin, M. Cho, D. Kush, et al. 2004. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol. 93: 1481-1486.
41. Tremblay, A. J., B. Lamarche, J. S. Cohn, J. C. Hogue, and P. Couture. 2006. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 26: 1101-1106.
42. Davis, H. R., Jr., K. K. Pula, K. B. Alton, R. E. Burrier, and R. W. Watkins. 2001. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism. 50: 1234-1241.
43. van Heek, M., D. S. Compton, and H. R. Davis. 2001. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol. 415: 79-84.
44. van Heek, M., C. Farley, D. S. Compton, L. Hoos, and H. R. Davis. 2001. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br. J. Pharmacol. 134: 409-417.
45. Lamon-Fava, S., M. R. Diffenderfer, P. H. Barrett, A. Buchsbaum, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, K. Horvath, B. F. Asztalos, V. Zago, et al. 2007. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res. 48: 1746-1753.
46. Ooi, E. M., G. F. Watts, D. C. Chan, M. M. Chen, P. J. Nestel, D. Sviridov, and P. H. Barrett. 2008. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care. 31: 1656-1661.
47. Scharnagl, H., R. Schinker, H. Gierens, M. Nauck, H. Wieland, and W. Matz. 2001. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem. Pharmacol. 62: 1545-1555.
48. Benitez, S., J. Ordonez-Llanos, M. Franco, C. Marin, E. Paz, J. Lopez-Miranda, C. Otal, F. Perez-Jimenez, and J. L. Sanchez-Quesada. 2004. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the lowdensity lipoprotein receptor. Am. J. Cardiol. 93: 414-420.
49. Boren, J., S. Rustaeus, and S. O. Olofsson. 1994. Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J. Biol. Chem. 269: 25879-25888.
50. Pal, S., E. Allister, A. Thomson, and J. C.Mamo. 2002. Cholesterol esters regulate apoB48 secretion in CaCo2 cells. Atherosclerosis. 161: 55-63.
51. Pau, E., Y. He, M. Lougheed, and U. P. Steinbrecher. 1995. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells. Biochem. Cell Biol. 73: 81-90.
52. Phillips, C., K. Mullan, D. Owens, and G. H. Tomkin. 2006. Intestinal microsomal triglyceride transfer protein in type 2 diabetic and nondiabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis. 187: 57-64.
53. Parhofer, K. G., E. Laubach, and P. H. Barrett. 2003. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J. Lipid Res. 44: 1192-1198.
54. Dane-Stewart, C. A., G. F. Watts, S. Pal, D. Chan, P. Thompson, J. Hung, and J. C. Mamo. 2003. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism. 52: 1279-1286.
55. Cianflone, K., M. Bilodeau, J. Davignon, and A. D. Sniderman. 1990. Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. Metabolism. 39: 274-280.
56. Cabezas, M. C., T.W. de Bruin, L. A. Kock,W. Kortlandt, M. Van Linde Sibenius Trip, H. Jansen, and D. W. Erkelens. 1993. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism. 42: 497-503.
57. Santos, R. D., A. C. Sposito, L. I. Ventura, L. A. Cesar, J. A. Ramires, and R. C. Maranhao. 2000. Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am. J. Cardiol. 85: 1163-1166.
58. Burnett, J. R., P. H. Barrett, P. Vicini, D. B. Miller, D. E. Telford, S. J. Kleinstiver, and M.W. Huff. 1998. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Arterioscler. Thromb. Vasc. Biol. 18: 1906-1914.
59. Sudhop, T., D. Lutjohann, A. Kodal, M. Igel, D. L. Tribble, S. Shah, I. Perevozskaya, and K. von Bergmann. 2002. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 106: 1943-1948.
60. Miettinen, T. A., T. E. Strandberg, andH. Gylling. 2000. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler. Thromb. Vasc. Biol. 20: 1340-1346.
61. Santosa, S., K. A. Varady, S. AbuMweis, and P. J. Jones. 2007. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci. 80: 505-514.